Differentiating COVID-19 patients from those with Influenza A or B (flu) will be especially important during the fall and winter months. Both types of infections can have very similar symptoms, and it may not be possible in many cases to differentiate based on clinical history alone.
BioReference Laboratories offers a multiplex test for flu and COVID-19 at the same time, using a single sample. This allows for more rapid diagnosis, conserves critical testing supplies, and provides surveillance for flu and COVID-19. Identifying the correct infectious agent, especially in high risk populations, will allow for early treatment and appropriate management.
- Multiplex testing only requires one sample collection, conserving valuable supplies
- Allows for rapid diagnosis
- Identifies the correct infectious agent for early and appropriate management
- Provides simultaneous testing for COVID-19 and flu viruses
According to the U.S. Centers for Disease Control and Prevention (CDC), both COVID-19 and flu can have varying degrees of signs and symptoms, ranging from no symptoms (asymptomatic) to severe symptom. The multiplex test for flu and COVID-19 test is for patients under investigation of COVID-19 or flu and seeking evaluation of active disease infection. Please refer to the most current CDC guidelines for further information.
M123 – COVID-19 + Influenza A/B
Specimens of patients under investigation of COVID-19 and seeking evaluation of the disease will not be collected at BioReference Patient Service Centers. Specimens should be collected at physician offices, hospitals or other clinic settings.
Please refer to the most current CDC guidelines for further information on collecting, handling, and testing clinical specimens here and the FDA FAQs on Diagnostic Testing for SARS-CoV-2 “What If I Do Not Have…?” here.
5 days at 2–8˚ C
2 days at 2–25˚ C followed by 3 days at 2–8˚ C
Frozen 30 days
- Positive 2019-nCoV
- Presumptive Positive 2019-nCoV
- Not Detected
- Flu A/B Detected